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Background. Joint symptoms (JSs) are problematic adverse drug reactions (ADRs) of aromatase inhibitors (AIs). Involvement of
decreased serum estradiol (SE) hasbeen suggested. PatientsandMethods.104 postmenopausalbreast cancer patients administered
an AI were prospectively investigated regarding various clinical parameters, JS and hot ﬂashesas ADRs, and the SElevel. Results.J S
manifestedin31.7%ofpatients andhotﬂashesin18.3%.Chi-squaretestingshowedasigniﬁcantlyhigherincidenceofJSinseveral
patientstrata:<55yearsold,decreased SE,andelevatedtotalcholesterol(TC).Inunivariateanalysis,JScorrelatedsigniﬁcantlywith
ap r e - A I%Y A Mo f≥80%, decreased SE, and elevated TC. Eight (7.7%) patients maintained SE at ≥5pg/mLfor>6c o n s e c u t i v e
months,withno JS.In chi-square testing, hot ﬂashesshowed a signiﬁcantlyhigher incidence in patients <55 years old. Conclusion.
AI-ADRs occurred more readily in younger patients. Decreased SE may be indirectly involved in JS.
1.Background
An aromatase inhibitor (AI) showed eﬃcacy that was supe-
rior to that of tamoxifen (TAM) in large-scale randomized
clinical trials in breast cancer patients, and AIs are now
the most extensively used drugs for postoperative adjuvant
therapy for hormone-dependent postmenopausal breast
cancer [1, 2]. However, on the minus side, manifestation
of joint symptoms (joint pain and stiﬀness) as drug-related
adverse reactions of AIs has become an important safety
issue. Joint symptoms have been variously reported to occur
at an incidence of 20% to 36% in patients administered AIs,
and discontinuation of administration of AIs is sometimes
unavoidable [3, 4]. It has been said that a decrease in
serum estrogen (E2) is associated with the causation of
joint symptoms due to AI administration [5–10]. However,
there have been no reports of stringent studies of such an
association, and the detailed mechanisms involved in any
such association thus remain unclear.
In recent years, there have been reports that AIs are
poorly metabolized in some patients [11], while in other
patients AIs do not show eﬃcacy because of genomic
polymorphism of the metabolizing enzymes [12]. Since
March of 2008 we have been monitoring the E2 levels in
breast cancer patients who were started on AI therapy, and
we reported that some patients show renewed elevation of
E2 in spite of being thought to be clinically postmenopausal
[13].
The present prospective study was designed with the
objective of elucidating whether or not there truly is an
association between manifestation of joint symptoms in
response to AI administration and a decrease in serum E2.
Accordingly, patients who were administered an AI were
monitored with regard to drug-related adverse reactions,
including joint symptoms, their clinical ﬁndings, and the E2
level. Statistical testing was performed to identify possible
signiﬁcant correlations.2 International Journal of Surgical Oncology
2.PatientsandMethods
A total of 159 hormone-dependent postmenopausal breast
cancer patients were started on administration of an AI at
Tokushima Breast Care Clinic during the period from March
2008 through October 2009. The AI treatment consisted
of anastrozole, in an oral dose of 1mg/day. Menopause
was deﬁned as the state of having undergone bilateral
oophorectomy, age of 60 years or older, or an age of under
60 years with amenorrhea for at least 12 months, and serum
E2, LH, and FSH levels that satisfy the diagnostic criteria
for postmenopause. For each enrolled patient, the following
information was elucidated and recorded: the patient’s age
at enrollment, age at menarche, number of childbirths,
BMI, age at menopause, time interval from menopause
until AI administration, presence/absence of therapy prior
to AI administration, and clinicopathological ﬁndings. In
addition, one adverse reaction of AI inhibitors is elevation
of serum cholesterol, a lipid metabolism abnormality [14].
For this reason, we carried out measurement of both E2
and total cholesterol in this study. The serum levels of total
cholesterol(TC)and E2were assayed priortoadministration
of the AI and then at 3, 6, 9, and 12 months after
starting the AI therapy. The TC assays were performed by
FALCO Biosystems Ltd. (Kyoto, Japan), and the serum E2
level was measured by ECLIA (electrochemiluminescence
immunoassay) in this laboratory. The laboratory’s standard
values for the postmenopausal levels of those hormones
are 130–219mg/dL for TC and 10–40pg/mL for E2 (lower
limit of detection: 5pg/mL). Patients who maintained E2
at ≥5pg/mL for more than 6 consecutive months following
the start of AI administration were classiﬁed as “rebound”
cases. All other patients were classiﬁed as “decreased” cases.
Patients who showed a transient increase or did not show an
initial decrease in E2 after the start of AI administration but
who then showed a decrease within 6 months following AI
administration were deﬁned as “decreased” cases.
Similarly, patients whose serum TC level was 10IU/mL
or more for at least 6 months following the start of AI
administration were classiﬁed as “elevated” cases, while all
other patients were classiﬁed as “nonelevated” cases. In
addition, the bone density was determined prior to the start
of AI administration and then every 4 months thereafter.
At each scheduled time of bone density testing the patients
were asked whether they experienced drug-related adverse
reactions, that is, joint symptoms and hot ﬂashes, which are
knowntooccurathighincidenceswithAIs.Thebonedensity
was measured on the basis of the speed of sound (SOS) for
propagation of an ultrasound pulse through the calcaneal
bone. The bone density was expressed as the percent of the
SOS relative to that of the young adult mean value (%YAM)
andthepercentoftheSOSrelativetothatoftheage-matched
meanvalue(%AGE).Patientsshowing adecreaseinthebone
density of 10% or more that persisted for at least 4 months
were classiﬁed as “decreased” cases, while all other patients
were classiﬁed as“nondecreased” cases. Drug-related adverse
reactions were evaluated in accordance with the Common
Terminology Criteria for Adverse Events (CTCAEs) Version
4.0 [15].
Table 1: The Clinicopathologicalcharacteristics (n = 104).
Stage
01 1
I5 8
II 35
Nodal status
n (−)7 9
n (+) 25
Therapy prior to AI administration
None 66
TAM 21
CT 10
TAM+LH-RH analogue 2
CT+TAM 4
CT+TAM+LH-RH analogue 1
The analyzed population of this study consisted of 104
patients who had not experienced joint symptoms or hot
ﬂashes prior to AI administration and were observed and
subjected to the above clinical testing for at least 6 months
subsequent to the start of AI administration. In addition,
patients who had ingested a concomitant medication that
could be thought to be related to an adverse reaction were
excluded from the analysis of that drug-related adverse
reaction.
Statistical analyses were performed using the chi-square
test and trend analysis by logistics regression analysis. A P
value of <.05 was deﬁned as representing a signiﬁcant diﬀer-
ence.
ThedesignofthisstudywasapprovedbytheEthicsCom-
mittee of The Institute of Medical Science, The University of
Tokyo, and The University of Tokushima (Protocol no.: 19-
11-1211). Prior informed consent was obtained in writing
from each of the enrolled patients.
3.Results
Itisnecessary toacknowledgethatalimitationofthisstudyis
that the study population was small. The clinicopathological
characteristics of the 104 analyzed patients were as follows.
The disease stage was Stage 0 in 11 patients, Stage I in 58
patients, and Stage II in 35 patients, and 25 patients had
axillary lymph node metastases. Sixty-six patients had not
received any treatment prior to AI administration, while 21
patients had been administered TAM monotherapy and 10
patients had received chemotherapy alone (Table 1).
The mean follow-up period for the 104 patients was 14.6
months, and 8 (7.7%) of the patients were classiﬁed as E2
rebound cases. In this study, patients who showed continu-
ousE2 elevation evenafterthe start ofAIadministration and
patients who showed no decrease in E2 after the start of AI
administration were classiﬁed as “rebound” cases. However,
because the sample size of this study was a bit small, these
two types ofpatients were pooled and analyzed as “rebound”
cases. In addition, because the lower limit ofdetection for E2
was 5pg/mL, it was impossible to identify patients whose E2International Journal of Surgical Oncology 3
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level did not decrease among the patients (32/104 patients;
30.8%) with a baseline E2 level below that lower limit of
detection.
The incidences of AI-related adverse reactions were
31.7% (33 patients) for joint symptoms and 18.3% (19
patients) for hot ﬂashes. The severity of the joint symptoms
was Grade 1 in 22 patients, Grade 2 in 7 patients, and Grade
3 in 4 patients.
Chi-square testing forpossible correlations betweenjoint
symptoms and various background factors found that the
incidence of joint symptoms was signiﬁcantly higher in the
patient group aged less than 55 years (P<. 05). In addition,
the patient group with less than a 5-year interval between
menopause and the start of AI therapy showed a tendency
to experience more joint symptoms than the patient group
with an interval of 10 or more years (P = .056). Moreover,
none of the patients in the E2 rebound patient group
experienced joint symptoms, and the incidence of joint
symptoms was signiﬁcantly lower than in the E2 decreased
patient group (P<. 05). The TC-elevated patient group
showed a signiﬁcantly higher incidence of joint symptoms
compared with the TC-nonelevated patient group (P<
.05). In univariate analysis, joint symptoms were found to
manifest at a signiﬁcantly higher incidence in the following
patient strata: a preAI %YAM of 80% or more (P<. 05),
E2 decreased (P<. 05), and TC elevated (P<. 01). The
time interval between menopause and the start of AI therapy
showed a tendency to inﬂuence the manifestation of joint
symptoms (P = .059). Multivariate analysis did not ﬁnd any
signiﬁcant correlations between the manifestation of joint
symptoms and the analyzed patient factors (Table 2).
Chi-square testing and univariate analysis for possible
correlationsbetweenhotﬂashesandvariousbackgroundfac-
tors found that the incidence of hot ﬂashes was signiﬁcantly
higherinthefollowing patientstrata: ageoflessthan55years
(P<. 05, P<. 05), menarche at an age of less than 12 years
(P<. 05, P<. 05), no prior therapy (chisquare testing only:
P<. 01), less than a 5-year interval between menopause and
the start of AI therapy (P<. 01, P<. 01), a preAI %YAM of
80% or more (P<. 05, P<. 01), and TC elevated (P<. 01,
P<. 05). Multivariate analysis did not ﬁnd any signiﬁcant
correlations between the manifestation ofhot ﬂashes and the
analyzed patient factors (Table 3).
4.Discussion
Aromatase inhibitors (AIs) are currently the drugs of choice
for postoperative adjuvant therapy for hormone-dependent
postmenopausalbreastcancer[1,2].However,manifestation
of joint symptoms (joint pain and stiﬀness) as drug-related
adversereactions ofAIshasbecomeanimportant safetyissue
[3, 4]. A decrease in E2 has been said to be one cause of the
joint symptoms associated with AI administration [5–10].
However, the possible mechanism of such causation remains
unclear, and there have been no stringent studies of such
an association between a decrease in E2 and manifestation
of joint symptoms. Accordingly, with the aim of elucidating
the detailed mechanisms involved in AI-related adverse
reactions, the present study was designed and executed by
prospectively surveying adverse reactions and measuring
the E2 level in postoperative postmenopausal breast cancer
patients who were administered an AI (anastrozole).
Joint symptoms manifested at an incidence of 31.7%
in these AI-treated patients, and they interfered with the
activities of daily life of approximately 4% of the patients. It
hasbeen said thatjointsymptoms inAI-treated patientstend
to occur more readily if the interval between menopause and
the start of AI therapy is within 5 years and if the patient’s
age is 50–59 years [16]. Our present study results also show
that joint symptoms tended to occur at a higher incidence
in younger patients, when the interval between menopause
and the start of AI therapy was shorter and when the pre-
AI %YAM was higher. It can thus be surmised that factors
associated with younger patients are more likely to lead to
manifestation of joint symptoms. Other factors that have
been suggested to be involved in the manifestation of joint
symptoms include the presence of prior therapy and obesity,
but the published literature does not show any consensus in
this regard [3, 5].
We also analyzed the manifestation of hot ﬂashes in
our study population. The incidence of hot ﬂashes in this
cohort was 18.3%, which was lower than the incidence of
jointsymptoms. However,hotﬂashes also tendedtomanifest
more frequently in the same younger patient population as
joint symptoms. TC elevation was associated with both joint
symptoms and hot ﬂashes, buta decrease in bone density did
not show any association with either adverse reaction. These
diﬀerencesmight be attributableto thefact thatTCelevation
is a change that manifests in a short time-frame, whereas a
decrease in bone density is a change that occursover a longer
period of time.
The E2 level was also analyzed for possible association
with the manifestation of AI-related adverse reactions. Our
results showed that hot ﬂashes were not associated with the
E2 level. Hot ﬂashes are considered to be a functional change
that occurs under sympathetic nerve stimulation due to a
decrease in E2, but it was reported that they do not correlate
with the E2 value [17]. Thus, it has been surmised that hot
ﬂashes do not occur as a result of a simple decrease in E2.
On the other hand, with regard to the possibility of
association of joint symptoms with E2, joint symptoms
did not occur in patients with E2 rebound, whereas their
manifestation was associated with a decrease in E2. How-
ever, multivariate analysis did not show a clear signiﬁcant
diﬀerence in relation to a decrease in E2. Accordingly, the
results indicated the possibility that a decrease in E2 is not
directlyassociated with manifestation ofjoint symptoms and
instead suggested the possibility that a decrease in E2 causes
some other secondary change(s) in joints, which is followed
by manifestation of joint symptoms.
Aromatase is present in osteoblasts, synovial cells, and
chondrocytes of articular cartilage, and one report surmised
that a local decrease in the E2 level in bones and joints
is involved in joint symptoms [4]. Some studies used
sonography and magnetic resonance imaging to objectively
investigate the local ﬁndings in patients with joint symptoms
due to AI therapy [18, 19]. It was reported that carpal tunnel
syndrome, wrist eﬀusion, tendon sheath enhancement and6 International Journal of Surgical Oncology
thickening, and tenosynovial changes were seen in patients
with joint symptoms due to AI therapy, ﬁndings that suggest
the possibility that joint symptoms are caused by secondary
organic changes that occur in joints.
For the present study, we used the ECLIA method to
measure the E2 levels; this method has a lower limit of
detection of 5pg/mL. This level of sensitivity can be con-
sidered a drawback of this study, since some of the enrolled
patients had an E2 level which was too low to detect even
before the start of AIadministration. Stanczyket al. reported
on the disadvantages of various E2 assay techniques [20].
A liquid chromatography-tandem mass spectrometry (LC-
MS/MS)method has become available in recent years, which
permits more sensitive assay of E2 [11, 21]. In the future, it
will be necessary to prospectively investigate organic changes
injointsduringAItherapybyusingthishighlysensitiveassay
technique to monitor E2 levels and also applying imaging
modalities. An additional drawback of our current study is
the small number of analyzed cases, and there is a need to
perform a future study in a larger cohort.
5.Conclusion
Alimitation of this study is thefact thatthe study population
wassmall.AI-relatedadversereactionsoccurredmorereadily
in younger patients, and the chi-square test and univariate
analysis both showed that a decrease in E2 was associated
with manifestation of joint symptoms. These results indicate
that joint symptoms due to AI therapy are aﬀected by a
decrease in E2. However, multivariate analysis did not show
anyclearassociation ofadecreaseinE2withjointsymptoms,
suggesting the possibility that a decrease in E2 is indirectly
involved in the manifestation of those symptoms.
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